![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.62 | -5.23648648649 | 11.84 | 11.96 | 11.06 | 17703 | 11.31575383 | DE |
4 | -0.84 | -6.96517412935 | 12.06 | 13 | 11.06 | 17147 | 12.25636225 | DE |
12 | -2.92 | -20.6506364922 | 14.14 | 14.14 | 11.06 | 19200 | 12.71018611 | DE |
26 | 0.14 | 1.26353790614 | 11.08 | 15.42 | 10.9 | 25486 | 12.99009434 | DE |
52 | -6.58 | -36.9662921348 | 17.8 | 19.18 | 7.89 | 35749 | 11.73790857 | DE |
156 | -20.03 | -64.096 | 31.25 | 36.7 | 5.6 | 31634 | 13.46614253 | DE |
260 | 1.54 | 15.9090909091 | 9.68 | 39 | 5.6 | 32971 | 17.06663397 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions